Insider Buying: Bluejay Diagnostics (NASDAQ:BJDX) Director Purchases 12,500 Shares of Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Donald Chase acquired 12,500 shares of the business’s stock in a transaction on Saturday, March 14th. The shares were purchased at an average price of $2.00 per share, for a total transaction of $25,000.00. Following the purchase, the director directly owned 12,525 shares of the company’s stock, valued at $25,050. This represents a 50,000.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bluejay Diagnostics Trading Up 3.0%

NASDAQ BJDX traded up $0.05 during trading hours on Monday, reaching $1.72. The company’s stock had a trading volume of 34,940 shares, compared to its average volume of 155,600. The stock has a market cap of $1.77 million, a PE ratio of -0.15 and a beta of 0.72. Bluejay Diagnostics, Inc. has a 52 week low of $1.63 and a 52 week high of $16.68. The business has a 50-day simple moving average of $1.90 and a 200 day simple moving average of $3.24.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.